Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug evaluation: E-5564.

Hari Kumar Ondiveeran1, Alison Fox-Robichaud

  • 1McMaster University, Department of Medicine, Regional Critical Care Programme and the Intestinal Disease Research Programme, Faculty of Health Sciences, HSC 4N52, 1200 Main St West, Hamilton, ON, L8N 3Z5, Canada.

Idrugs : the Investigational Drugs Journal
|June 16, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mouse models to study von Willebrand factor in inflammation: a scoping review.

Intensive care medicine experimental·2026
Same author

Bridging the Gap in Sepsis Recovery: A Scoping Review of Post-Discharge Care Interventions.

Journal of intensive care medicine·2026
Same author

Publisher Correction: Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026.

Intensive care medicine·2026
Same author

Sepsis policy, guidelines, and standards in Canada: a jurisdictional scoping review.

BMC health services research·2026
Same author

Collecting Accurate and Robust Equity (CARE) data: an analysis of a pilot quality improvement initiative in ambulatory settings.

BMJ open quality·2026
Same author

Executive Summary: Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026.

Critical care medicine·2026
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Eisai Co Ltd is developing E-5564, an injectable endotoxin antagonist, to prevent severe responses to bacterial infections. This drug aims to mitigate the effects of endotoxin-mediated conditions like septic shock.

Area of Science:

  • Pharmacology
  • Immunology
  • Infectious Diseases

Background:

  • Bacterial infections can trigger dangerous endotoxin-mediated responses.
  • Septic shock is a life-threatening condition resulting from such responses.

Purpose of the Study:

  • To evaluate the potential of E-5564 as an endotoxin antagonist.
  • To investigate the prevention of pathophysiological effects caused by bacterial infections.

Main Methods:

  • Development of injectable endotoxin antagonist E-5564.
  • Preclinical and/or clinical studies to assess efficacy and safety.

Main Results:

  • E-5564 demonstrated potential in preventing endotoxin-mediated effects.
  • Further research is ongoing to confirm its therapeutic value.

Related Experiment Videos

Conclusions:

  • E-5564 shows promise as a novel therapeutic agent.
  • This endotoxin antagonist could offer a new strategy for managing severe bacterial infections and septic shock.